Avitide

Executive Summary

Avitide is a biotechnology company specializing in the development and supply of proprietary affinity purification solutions for the biopharmaceutical manufacturing industry. Founded in 2011 and headquartered in Lebanon, New Hampshire, the company's AVIPure™ affinity resins are designed to enhance purity, yield, and efficiency in the production of a wide range of drug modalities, including antibodies, gene therapies, and vaccines. By offering custom and platform purification resins from development through commercial supply, Avitide positions itself as a critical technology provider and manufacturing partner for biopharma companies seeking to optimize downstream processing. As the demand for biologics and advanced therapies continues to grow, Avitide's solutions address key bottlenecks in purification, potentially reducing costs and improving scalability for manufacturers. The company operates in a competitive landscape dominated by established players like Cytiva and Thermo Fisher, but Avitide differentiates through its focus on custom, high-performance resins tailored to specific client needs. Its technology is particularly relevant for novel modalities such as gene therapies and mRNA-based vaccines, where traditional purification methods often fall short. With a strong emphasis on R&D and customer collaboration, Avitide has the potential to capture significant market share as biopharmaceutical companies increasingly adopt advanced purification technologies. However, as a private company, its financial performance and growth trajectory remain opaque, and its success depends on continued innovation, regulatory adoption of its resins, and expansion of its commercial partnerships.

Upcoming Catalysts (preview)

• Q4 2026Expansion of AVIPure platform to gene therapy applications60% success